Home
About NETRF

About
NETRF

Our Story

NETRF Team

Board of Directors

Board of Scientific Advisors

Diversity & Inclusion

Financial Stewardship & Accountability

Careers at NETRF

The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $36 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.

DONATE
For Patients

For
Patients

About NETs

Newly Diagnosed

NET Tests and Treatments

Find a NET Specialist or Support Group

Order Your Free Neuroendocrine Cancer Guide

Living with NETs

Patient Stories

Tumor Tissue Donation

NETWise Podcast

Recursos en espanol aqui
For Researchers

For Researchers

About our Research

Our Strategy

Our Impact

Research Portfolio

Funding for Researchers

Apply for Grants

Research Symposium

Cell Line Project

The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $36 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.

DONATE
Get Involved

Get
Involved

Support NET Research

Give Now

Ways to Give

What Your Gift Supports

Donor Stories

Fundraising Events

Memorial Gifts

Everlasting Impact Tributes

Planned Giving
Events

NETRF Funded Research Projects

uPAR-targeted PRRT: new radionuclide-based therapy

Andreas Kjaer, MD, PhD, DMSc

Understanding the tumor suppressor activities of ATRX-DAXX through epigenomic profiling and animal models

Peter Lewis, PhD; C. David Allis, PhD

Understanding the physiologically relevant functions of Daxx

Guillermina (Gigi) Lozano, PhD

Understanding the genetic and cellular origins of carcinoid cancer

Ramesh Shivdasani, MD, PhD,

Tumor-Specific Delivery of Temozolomide to Overcome Resistance in GEP-NET

Ali Azhdarinia, PhD

Tumor xenografts in zebrafish: a new in vivo model for lung carcinoids

Giovanni Vitale, MD, PhD

About NETRF

ForPatients

For Researchers

Get Involved

NETRF Funded Research Projects

uPAR-targeted PRRT: new radionuclide-based therapy

Understanding the tumor suppressor activities of ATRX-DAXX through epigenomic profiling and animal models

Understanding the physiologically relevant functions of Daxx

Understanding the genetic and cellular origins of carcinoid cancer

Tumor-Specific Delivery of Temozolomide to Overcome Resistance in GEP-NET

Tumor xenografts in zebrafish: a new in vivo model for lung carcinoids

About
NETRF

For
Patients

Get
Involved